Johnson & Johnson (JNJ)vsMedpace Holdings Inc (MEDP)
JNJ
Johnson & Johnson
$227.35
+1.10%
HEALTHCARE · Cap: $547.28B
MEDP
Medpace Holdings Inc
$413.59
+0.96%
HEALTHCARE · Cap: $11.81B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 3498% more annual revenue ($96.36B vs $2.68B). JNJ leads profitability with a 21.8% profit margin vs 17.2%. MEDP appears more attractively valued with a PEG of 2.54. MEDP earns a higher WallStSmart Score of 66/100 (B-).
JNJ
Buy59
out of 100
Grade: C
MEDP
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-43.5%
Fair Value
$160.13
Current Price
$227.35
$67.22 premium
Margin of Safety
-5.3%
Fair Value
$402.51
Current Price
$413.59
$11.08 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Every $100 of equity generates 77 in profit
Strong operational efficiency at 20.0%
Revenue surging 26.5% year-over-year
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
Moderate valuation
Expensive relative to growth rate
Trading at 25.6x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bull Case : MEDP
The strongest argument for MEDP centers on Return on Equity, Operating Margin, Revenue Growth. Profitability is solid with margins at 17.2% and operating margin at 20.0%. Revenue growth of 26.5% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : MEDP
The primary concerns for MEDP are P/E Ratio, PEG Ratio, Price/Book.
Key Dynamics to Monitor
JNJ profiles as a mature stock while MEDP is a growth play — different risk/reward profiles.
MEDP carries more volatility with a beta of 1.39 — expect wider price swings.
MEDP is growing revenue faster at 26.5% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
MEDP scores higher overall (66/100 vs 59/100), backed by strong 17.2% margins and 26.5% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Medpace Holdings Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company is headquartered in Cincinnati, Ohio.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?